Announcements

March 14, 2017

Call for Proposals: Creative Computational Approaches to Accelerate Drug Discovery for the Treatment and Prevention of Dementia

The Alzheimer's Drug Discovery Foundation (ADDF) Program on Aging and Alzheimer's Disease Prevention invites scientists to apply for grants on innovative computational approaches to map disease and predict the efficacy of drugs to treat and prevent dementia. Grants will be provided for one-year duration (up to $150,000 each) with the possibility of follow-on funding. The deadline date for application for this grant is September 5, 2013.

More information regarding the Call is attached.  Information on other grants announced by the Alzheimer's Drug Discovery Foundation may also be found at www.alzdiscovery.org/research-and-grants/request-for-proposal.

March 14, 2017

2013 Geoffrey Beene Global NeuroDiscovery Challenge

The Geoffrey Beene Foundation Alzheimer'ss Initiative has announced its second online innovation challenge whose goal is to identify male and female differences in the pathogenesis and presentation of Alzheimer's disease in the pre-symptomatic, early symptomatic and late stages of the disease. The Challenge will require a written proposal and winning submissions will share $100,00 in prize awards.

More information is attached, and may also be found at http://geoffreybeenechallenge.org/challenge/

March 14, 2017

The Association for Frontotemporal Degeneration (AFTD): Request for Proposals (2013 Pilot Research Grants)

The AFTD has issued a Request for Proposals for pilot grants that are designed to seed original projects, with the goal of generating preliminary data towards a larger grant application on basic/clinical research in frontotemporal degeneration and related conditions.

Applications are due on July 1, 2013.

More information may be found at www.theaftd.org/research/aftd-research-initiatives/current-rfps, or on the attached document.

Attachment: 

March 14, 2017

Call for Applications: 2013 Neurodegenerative Diseases Pilot Study Grants Program

The Massachusetts Alzheimer's Disease Research Center, the Harvard NeuroDiscovery Cener, and the MGH Neurological Clinical Research Institute have joined forces to fund the best novel ideas for pilot projects aimed at uncovering and developing effective treatments for neurodegenetive diseases.

Applications are due on Thursday, December 6, 2012.

The Call for Applications is attached.

March 14, 2017

Harvard Magazine (November - December, 2012): Boston Hospitals: Curing Disease, Improving Lives

Boston is a mecca of medicine, home to some of the most prestigious hospitals and medical schools, physicians and medical scientists in the world. Since the momentous day in 1846 when William Morton, a local dentist, for the first time publicly demonstrated the use of inhaled ether as a surgical anesthetic in Masachusetts General Hospital's now-famous Ether Dome, the city has seen many medical firsts, including the first fertilization of an ovum in a test tube and the first successful human-organ transplant. Today, it ranks as a preeminent center for healthcare and research. They city and its environs are home to top colleges and universities, and eastern Massachusetts, inside the Route 495 corridor, houses many leading biotechnology companies, providing both the brainpower and the cutting-edge research and product development necessary for quality care.

Boston proper is also home to more the 20 hospitals - from giants like mass General, Boston Children's Hospital, and Brigham and Women's Hospital (BWH) to specialty institutions such as Arbour Hospital for psychiatric care and Jewish Memorial Hospital for long-term care.

http://harvardmagazine.com/2012/11/boston-hospitals

March 14, 2017

Harvard Medical School (July 17, 2012): Mass General Hospital Ranked No. 1

Mass General, the largest teaching affiliated of Harvard Medical School, has traditionally ranked among the top hospitals in the nation since the survey began in 1990, but this year was the first time the 950-bed medical center unseated Johns Hopkins Hospital in Baltimore, which has held the top position for the past 21 years. To be nationally ranked, a hospital must excel across a range of tough cases within a given specialty, and the survey ranks hospitals in 16 different care specialties, according to the magazine.

"This recognition is a tribute to the more than 23,000 staff members at Mass General who are dedicated to delivering the hightest quality care to patients and families. Our employees are the ones who have built and shaped Mass General into the extraordinary health care resource it has been for the past 200 years and will continue to be in the future," said Mass General Hosptial President Peter L. Slavin.

http://hms.harvard.edu/content/mass-general-hospital-ranked-no-1

March 14, 2017

Request for Applications: 2012 Harvard/MIT Join Research Grant Program in Basic Neuroscience

The Harvard NeuroDiscovery Center (www.neurodiscovery.harvard.edu) is pleased to announce the 3rd year of a major funding opportunity for collaborative basic neuroscience research across the Harvard and MIT communities. Up to 5 $200,000 grants ($100,000 per year for 2 years) may be awarded each year.

The deadline for this year's application is September 1, 2012.

Please refer to the attached documents for more specific details.

March 14, 2017

2012 Neurodegenerative Diseases Pilot Study Grants Program

The Massachusetts ADRC, Harvard NeuroDiscovery Center and the MGH Neurology Clinical Trials Unit have joined forces to fund the best novel ideas for pilot projects aimed at understanding and developing treatments for neurodegenerative diseases. Together, we are pleased to announce a joint call for pilot study applications from investigators within the Harvard community, including the affiliated hospitals and institutions. In addition, investigators from the University of Massachusetts community are encouraged to submit ALS-related purposals. Grants with a dollar value up to $40,000 (direct costs) will be awarded for the duration of one-year. A total of $400,000 is available.

Applications will be judged on the basis of scientific merit, novelty and the value of the project in obtaining preliminary data that could lead to sponsored research (investigator-initiated R01 research grants, career development awards, industry or foundation support). Availability of appropriate facilities and the technical ability to carry out the project are fundamental. Clinical projects as well as basic research will be considered. Priority will be given first to junior investigators, then to senior investigators who are new to neurodegenerative disease research, and finally, to established investigators with a new line of investigation that lacks funding. Use of Harvard NeuroDiscovery Center cores, ADRC cores or MGH Neurology Clinical Trials Unit resources is strongly encouraged.

All applications should be prepared according to the same rules and criteria and submitted electronically to neurodiscovery@hms.harvard.edu by 5pm November 18th, 2011.

More information on the program may be found at neurodiscovery.harvard.edu

Applications Due Date:  November 18, 2011
Recipients Announced:  December 15, 2011
Awards Start:  January - April 2012

March 14, 2017

Request for Applications: 2011 Harvard/MIT Join Research Grant Program in Basic Neuroscience

The Harvard NeuroDiscovery Center (www.neurodiscovery.harvard.edu) is pleased to announce the 2nd year of a major funding opportunity for collaborative basic neuroscience research across the Harvard and MIT communities. Up to 5 $200,000 grants ($100,000 per year for 2 years) may be awarded each year.

The deadline for this year's application is September 1, 2011.

Please refer to the attached documents for more specific details.

 

March 14, 2017

Call for Proposals: ADDF and the AFTD Invite Scientists to Apply for FTD Biomarker Grants

The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) invite scientists from academia and the biotechnology industry worldwide to apply for research grants to develop Frontotemporal Dementia-specified biomarkers that reflect pathological and clinical differences so that appropriate patients can be selected for clinical trials and responses to investigational treatments can be monitored.

More information regarding the Call is attached, and may also be found at www.theaftd.org/research/aftd-research-initiatives/current-rfps

Pages